Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
influenza messenger RNA vaccine (GSK)
- Development stage
- Approved
- Lead developer
- GSK
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
An influenza messenger RNA (mRNA) vaccine is a prophylactic biologic that utilizes synthetic mRNA to encode viral antigens, primarily the hemagglutinin (HA) protein of influenza A and B viruses. Upon administration, the mRNA is translated by host cells to produce the target antigens, which then elicit neutralizing antibody and T-cell responses. This platform offers advantages over traditional egg-based manufacturing, including faster production timelines and the potential for improved strain matching. Key candidates in this space include GSK's multivalent vaccines (e.g., GSK4382276A, developed in collaboration with CureVac), which have progressed to Phase 3 development after demonstrating positive immunogenicity and safety in Phase 2 trials. Other developers active in this platform include Moderna, Pfizer, and Flag Bio.
- Other names
- mRNA-based multivalent seasonal influenza vaccineAnti-flu mRNA vaccine
02
Targets
DHX58 (DExH-box helicase 58)NLRP3 (Nod-like receptor family pyrin domain-containing protein 3)TLR7/8 (Toll-like receptor 7 and Toll-like receptor 8)HA0 (Influenza B virus hemagglutinin)Host ribosomal translation machinery
Beyond the preview
Go deeper on influenza messenger RNA vaccine (GSK).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on influenza messenger RNA vaccine (GSK).